Replies to post #444528 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

You make a (highly unlikely) assumption against the evidence that ALL to protocol endpoints of the P2b/3 AD trial were met.

[Joseph_K]

My assertion that misinformation likely was issued is not a mere assumption, since it's based on evidence (though I can't be positive it's correct). I've already told you the primary reasons I believe the ADL endpoint was not met: "I don't believe it met the ADL endpoint because I believe my friend that the SAP says the analysis will be difference of means; and because the Kun Jin PR announcing the 0.025s would certainly have said how ADL met the prescribed endpoint if it had." And I've said why I believe Anavex mistakenly claimed endpoints were all met: chaos when they felt they had to make a major presentation based on data that had been statistically analyzed by the CRO, not by Anavex, and was received an absurdly short one day before that presentation.

Your primary reason for believing the ADL endpoint was met is that the company said so, but you can't be positive that that claim was correct, either; and there's evidence indicating it wasn't.